TGF-β / Smad Signaling
The TGF-β family is generally classified into two sub-families, TGF-β ligands, and bone morphogenic protein (BMP) ligands. In canonical signaling, receptor activation lead to phosphorylation of a group of transcription factors called Smads. TGF-β ligands bind to type II receptors (TGF-β II) which recruit and phosphorylate type I receptor (TGF-β I) on serine/threonine residues. The TGF-β I then recruits and phosphorylates a receptor regulated Smad (R-Smad). The R-Smad binds to the common Smad (Co-Smad) and forms a heterodimeric complex. This complex then translocates into the cell nucleus where it binds with nuclear co-factors to regulate the transcription of various target genes. Dysregulation of TGF-β/Smad signaling pathway is associated with a number of pathological conditions including fibrosis, cancer, immunodeficiency, diabetes and cardiovascular diseases etc.
- B1294 SR-3677Target: ROCKSummary: Rho Kinase (ROCK-II) inhibitor
- B4942 Bryostatin 2Summary: Protein kinase C (PKC) activator
- B4943 Bryostatin 3Summary: protein kinase C activator
- B5863 LX7101 HCLSummary: Dual LIM-kinase and ROCK inhibitor
- B5954 Dasatinib MonohydrateTarget: PDGFR|c-Kit|Bcr-Abl|SrcSummary: Inhibitor of ABL, SRC, KIT, PDGFR, and other tyrosine kinases.
- B6066 Bisindolylmaleimide VSummary: negative control for protein kinase C (PKC)-inhibitory activity
- B2191 Dequalinium ChlorideTarget: PKC|Calcium-Activated Potassium (KCa) ChannelsSummary: anti-tumor agent and PKC inhibitor
- B2287 LY3649471 CitationSummary: inhibitor of TGF-β type I receptor kinase domain
- B2288 PirfenidoneSummary: TGF-β production inhibitor
- B3392 GSK269962ATarget: ROCK|RSK|MSKSummary: ROCK inhibitor